These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36933171)

  • 1. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
    Blakeley J
    Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis.
    González-Rodriguez MA; Troutman S; Bayle S; Lester DK; Grove M; Duckett D; Kareta MS; Kissil JL
    Oncogene; 2024 Sep; 43(40):2995-3002. PubMed ID: 39209965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology of vestibular schwannomas.
    Chang LS; Welling DB
    Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular biology and novel treatments of vestibular schwannomas.
    Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
    J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofibromatosis type 2.
    Slattery WH
    Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromatosis Type 2: Multiple Meningiomatosis and Vestibular Schwannomas on 68 Ga-DOTATATE PET/CT.
    Filizoglu N; Ozguven S
    Clin Nucl Med; 2022 Nov; 47(11):e710-e712. PubMed ID: 35961372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.
    Dewan R; Pemov A; Kim HJ; Morgan KL; Vasquez RA; Chittiboina P; Wang X; Chandrasekharappa SC; Ray-Chaudhury A; Butman JA; Stewart DR; Asthagiri AR
    Neuro Oncol; 2015 Apr; 17(4):566-73. PubMed ID: 25452392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
    Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
    Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
    Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
    Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of multiple tumors in neurofibromatosis type 2 patients.
    Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
    Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
    Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
    J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders.
    Mills JR; Moyer AM; Kipp BR; Poplawski AB; Messiaen LM; Babovic-Vuksanovic D
    Clin Genet; 2018 Jan; 93(1):187-190. PubMed ID: 28737257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.